UNSPSC 51433921: Nicardipine

This classification denotes a calcium channel blocker with the molecular formula C26H29N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZ5312222S, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester but generally known as nicardipine, which bears US NIH Compound Identifier 4474. European Medicines Agency schedules Nicardipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09225MIG.

UNSPSC 51433921 Nicardipine is a Commodity code designating a specific antihypertensive and vasodilator medication supplied to state and local emergency medical services, healthcare systems, and pharmacy benefit programs. State and local governments procure nicardipine as part of broader advanced life support medication portfolios for fire rescue departments, emergency response units, and multi-jurisdictional pharmacy initiatives. Issuing bodies include city purchasing departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across state and local members. Recent solicitations show nicardipine purchased alongside labetalol, epinephrine, adenosine, and diltiazem as part of standardized emergency medication supply contracts with firm expiration-date requirements (nine months minimum from acceptance) and single-year terms with renewal options.

The code shows recent activity in Florida and Minnesota-based cooperative purchasing. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue in Hillsborough County, with a $40,000 estimated value and electronic bid submission through OpenGov eProcurement by April 8, 2026; the solicitation carried a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products with an RFP response deadline of March 26, 2026, establishing two-year contracts effective July 1, 2026, with authorized wholesaler distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs, signaling exploratory procurement activity in pharmaceutical supply structure across state systems.